Anika Therapeutics, Inc.ANIKNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P26
Within normal range
vs 5Y Ago
-0.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -7.11% |
| Q3 2025 | 10.03% |
| Q2 2025 | 4.19% |
| Q1 2025 | 121.29% |
| Q4 2024 | -62.20% |
| Q3 2024 | 8.41% |
| Q2 2024 | -18.15% |
| Q1 2024 | 7.63% |
| Q4 2023 | -2.64% |
| Q3 2023 | -12.60% |
| Q2 2023 | 6.12% |
| Q1 2023 | 8.40% |
| Q4 2022 | 6.14% |
| Q3 2022 | 4.67% |
| Q2 2022 | 13.29% |
| Q1 2022 | 2.62% |
| Q4 2021 | -21.80% |
| Q3 2021 | 5.21% |
| Q2 2021 | 14.65% |
| Q1 2021 | -16.65% |
| Q4 2020 | 46.29% |
| Q3 2020 | 15.11% |
| Q2 2020 | -25.09% |
| Q1 2020 | 48.14% |
| Q4 2019 | -1.78% |
| Q3 2019 | -0.17% |
| Q2 2019 | -2.18% |
| Q1 2019 | 4.77% |
| Q4 2018 | -3.97% |
| Q3 2018 | -10.59% |
| Q2 2018 | -8.29% |
| Q1 2018 | 20.98% |
| Q4 2017 | -26.98% |
| Q3 2017 | 31.31% |
| Q2 2017 | 5.18% |
| Q1 2017 | 42.95% |
| Q4 2016 | 4.85% |
| Q3 2016 | 1.07% |
| Q2 2016 | 29.32% |
| Q1 2016 | -28.42% |